Toronto-based NoNO Inc. announced results from the pivotal Phase III ESCAPE-NA1 trial of intravenous nerinetide in patients with acute ischemic stroke who were chosen to undergo endovascular thrombectomy.
https://www.pharmalive.com/wp-content/uploads/2020/02/NoNO-Stroke-Study-BioSpace-2-21-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-02-21 12:05:402020-02-25 01:28:28NoNO’s Stroke Trial Could Have Major Implications for Future Treatment